Cevdet Aydin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cevdet Aydin has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Oya Topaloğlu
Ankara Yildirim Beyazıt University, Faculty of Medicine, Department of Endocrinology and Metabolism
10 shared publications - Bekir Çakır
Ankara Yildirim Beyazıt University, Faculty of Medicine, Department of Endocrinology and Metabolism
9 shared publications - Reyhan Ersoy
Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara 06010, Türkiye
8 shared publications - Ekin Yiğit Köroğlu
Department of Endocrinology and Metabolism, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
5 shared publications - Berna Evranos
Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara 06800, Turkey
4 shared publications - Fatma Dilek Dellal
Department of Endocrinology and Metabolism, Ankara Bilkent City Hospital, Ankara 06800, Turkey
4 shared publications
Latest Publications
- 28 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 313
Clinical, ultrasonographic, and cytological characteristics of niftp and postoperative outcomes: a retrospective cohort study
- 28 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 313
Clinical, ultrasonographic, and cytological characteristics of niftp and postoperative outcomes: a retrospective cohort study
- Open Access
- 25 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Surgical extent, tumor size, and calcitonin levels in medullary thyroid carcinoma: impact on oncologic outcomes in a retrospective cohort study
Medullary thyroid carcinoma (MTC) treatment guidelines recommend surgical extent based primarily on calcitonin levels, yet the oncologic impact of deviatin
- 25 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessSurgical extent, tumor size, and calcitonin levels in medullary thyroid carcinoma: impact on oncologic outcomes in a retrospective cohort study
Medullary thyroid carcinoma (MTC) treatment guidelines recommend surgical extent based primarily on calcitonin levels, yet the oncologic impact of deviatin
- Open Access
- 8 April 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
- Vol. 30 (2)
From Corticotropin-Releasing Hormone to the Desmopressin Era: A Comparative Study of Stimulation Tests in Cushing’s Disease
Objective: The discontinuation of corticotropin-releasing hormone (CRH) production has shifted clinical practice toward the use of desmopressin for dynamic stimulation testing in the diagnosis of Cushing’s disease (CD). However, comparative data on the responses to CRH and desmopressin remain limited. This study aimed to compare the responses of adrenocorticotropic hormone (ACTH)- secreting pituitary adenomas to desmopressin and CRH stimuli. Methods: This study included patients with histopathologically confirmed CD who underwent a CRH or desmopressin stimulation test between 2019 and 2024. After an overnight fast, baseline ACTH and cortisol levels were measured at −15 and 0 minutes. The CRH (100 mcg IV bolus) or desmopressin (10 mcg IV over 15 minutes) was administered, and blood samples were collected at 15, 30, 45, 60, 90, and 120 minutes. The primary outcomes were peak ACTH and cortisol levels, percentage increases from baseline (ΔACTH% and ΔCort%), and the timing of peak response. Results: A total of 30 patients (27 females and 3 males) were included; 18 underwent CRH, and 12 underwent desmopressin stimulation. The 2 groups had no significant difference in basal ACTH, basal cortisol, peak ACTH, and peak cortisol levels (P > .05). The CRH elicited a significantly greater increase in ACTH (ΔACTH%: 340.6% Å} 271.4 vs. 159.9% Å} 105.3, P = .038) and cortisol (ΔCort%: 77.9% Å} 50.3 vs. 43.0% Å} 26.1, P = .021) compared to desmopressin. Peak hormone responses occurred at similar time points in both tests. Conclusion: The CRH stimulates ACTH and cortisol secretion more effectively than desmopressin. Current diagnostic thresholds may not directly apply to desmopressin, potentially leading to falsenegative results. Larger studies are needed to establish standardized criteria for desmopressin-based CD diagnosis. Cite this article as: Köroğlu EY, Polat ŞB, Tam AA, et al. From corticotropin-releasing hormone to the desmopressin era: A comparative study of stimulation tests in Cushing’s disease. Endocrinol Res Pract. 2026;30(2):105-111.
- 8 April 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
- Vol. 30 (2)
Open AccessFrom Corticotropin-Releasing Hormone to the Desmopressin Era: A Comparative Study of Stimulation Tests in Cushing’s Disease
Objective: The discontinuation of corticotropin-releasing hormone (CRH) production has shifted clinical practice toward the use of desmopressin for dynamic stimulation testing in the diagnosis of Cushing’s disease (CD). However, comparative data on the responses to CRH and desmopressin remain limited. This study aimed to compare the responses of adrenocorticotropic hormone (ACTH)- secreting pituitary adenomas to desmopressin and CRH stimuli. Methods: This study included patients with histopathologically confirmed CD who underwent a CRH or desmopressin stimulation test between 2019 and 2024. After an overnight fast, baseline ACTH and cortisol levels were measured at −15 and 0 minutes. The CRH (100 mcg IV bolus) or desmopressin (10 mcg IV over 15 minutes) was administered, and blood samples were collected at 15, 30, 45, 60, 90, and 120 minutes. The primary outcomes were peak ACTH and cortisol levels, percentage increases from baseline (ΔACTH% and ΔCort%), and the timing of peak response. Results: A total of 30 patients (27 females and 3 males) were included; 18 underwent CRH, and 12 underwent desmopressin stimulation. The 2 groups had no significant difference in basal ACTH, basal cortisol, peak ACTH, and peak cortisol levels (P > .05). The CRH elicited a significantly greater increase in ACTH (ΔACTH%: 340.6% Å} 271.4 vs. 159.9% Å} 105.3, P = .038) and cortisol (ΔCort%: 77.9% Å} 50.3 vs. 43.0% Å} 26.1, P = .021) compared to desmopressin. Peak hormone responses occurred at similar time points in both tests. Conclusion: The CRH stimulates ACTH and cortisol secretion more effectively than desmopressin. Current diagnostic thresholds may not directly apply to desmopressin, potentially leading to falsenegative results. Larger studies are needed to establish standardized criteria for desmopressin-based CD diagnosis. Cite this article as: Köroğlu EY, Polat ŞB, Tam AA, et al. From corticotropin-releasing hormone to the desmopressin era: A comparative study of stimulation tests in Cushing’s disease. Endocrinol Res Pract. 2026;30(2):105-111.
- Open Access
- 1 March 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Evaluation of ultrasonographic and clinicopathological features of patients with abnormal [68Ga]Ga-DOTA-TATE uptake in the thyroid gland
Background: [ 68 Ga]Ga-DOTA-TATE PET/CT is primarily used for imaging neuroendocrine tumors, yet incidental thyroid uptake is observed in 7–11% of scans. While focal uptake has been associated with an increased risk of malignancy, the ultrasonographic and pathological features of these cases remain underexplored. This study aimed to investigate the ultrasonographic and clinicopathological features of patients with abnormal [ 68 Ga]Ga-DOTA-TATE uptake in the thyroid gland. Results: Among 2,971 patients who underwent [ 68 Ga]Ga-DOTA-TATE PET/CT between April 2019 and November 2023, abnormal thyroid uptake was detected in 154 patients (5.2%). Of these, 39 patients with complete ultrasonographic evaluation constituted the final analytical cohort and were included in the detailed clinicopathological analysis. Uptake was focal in 59%, diffuse in 17.9%, and heterogeneous in 23.1% of cases. Fine-needle aspiration biopsy (FNAB) was performed in 24 patients, with 41.7% yielding non-diagnostic results. Only one case of papillary thyroid carcinoma was detected, corresponding to a 2.6% malignancy rate. Diffuse uptake was commonly linked to Hashimoto’s thyroiditis. A moderate inverse correlation was observed between SUVmax and BMI ( r = − 0.54, p < 0.05), with a mean SUVmax of 7.35 ± 3.08. Conclusions: Focal [ 68 Ga]Ga-DOTA-TATE thyroid uptake may suggest malignancy, though the observed malignancy rate in our cohort was lower than previously reported. Diffuse uptake was generally associated with benign inflammatory conditions. The inverse association between SUVmax and BMI is a novel finding warranting further investigation. Comprehensive evaluation, including ultrasonography and FNAB, is advised for patients with incidental focal uptake.
- 1 March 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Open AccessEvaluation of ultrasonographic and clinicopathological features of patients with abnormal [68Ga]Ga-DOTA-TATE uptake in the thyroid gland
Background: [ 68 Ga]Ga-DOTA-TATE PET/CT is primarily used for imaging neuroendocrine tumors, yet incidental thyroid uptake is observed in 7–11% of scans. While focal uptake has been associated with an increased risk of malignancy, the ultrasonographic and pathological features of these cases remain underexplored. This study aimed to investigate the ultrasonographic and clinicopathological features of patients with abnormal [ 68 Ga]Ga-DOTA-TATE uptake in the thyroid gland. Results: Among 2,971 patients who underwent [ 68 Ga]Ga-DOTA-TATE PET/CT between April 2019 and November 2023, abnormal thyroid uptake was detected in 154 patients (5.2%). Of these, 39 patients with complete ultrasonographic evaluation constituted the final analytical cohort and were included in the detailed clinicopathological analysis. Uptake was focal in 59%, diffuse in 17.9%, and heterogeneous in 23.1% of cases. Fine-needle aspiration biopsy (FNAB) was performed in 24 patients, with 41.7% yielding non-diagnostic results. Only one case of papillary thyroid carcinoma was detected, corresponding to a 2.6% malignancy rate. Diffuse uptake was commonly linked to Hashimoto’s thyroiditis. A moderate inverse correlation was observed between SUVmax and BMI ( r = − 0.54, p < 0.05), with a mean SUVmax of 7.35 ± 3.08. Conclusions: Focal [ 68 Ga]Ga-DOTA-TATE thyroid uptake may suggest malignancy, though the observed malignancy rate in our cohort was lower than previously reported. Diffuse uptake was generally associated with benign inflammatory conditions. The inverse association between SUVmax and BMI is a novel finding warranting further investigation. Comprehensive evaluation, including ultrasonography and FNAB, is advised for patients with incidental focal uptake.
- 3 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3264-3272
Relationship between body mass index and 1 mg dexamethasone suppression test in patients with obesity
Aims: The 1 mg dexamethasone suppression test (DST) shows variable results in obesity, yet the impact of extreme obesity (body mass index [BMI] ≥50 kg/m 2 ) on hypothalamic–pituitary–adrenal axis function remains poorly characterized. This study evaluated post‐dexamethasone cortisol levels across distinct BMI categories and their associations with metabolic parameters. Materials and Methods: This retrospective study included 352 adults with obesity (BMI ≥30 kg/m 2 ) who underwent 1 mg overnight DST between February 2019 and August 2023. Patients were stratified into three groups: BMI 30.0–39.9 kg/m 2 ( n = 64), BMI 40.0–49.9 kg/m 2 ( n = 202), and BMI ≥50.0 kg/m 2 ( n = 86). Clinical, anthropometric, and laboratory parameters were compared between groups. Results: The cohort had a median age of 41 years and comprised 284 females (80.7%). Post‐dexamethasone cortisol levels showed modest differences across BMI categories (median 0.79, 0.77, and 0.88 μg/dL, respectively; p = 0.038). Inadequate cortisol suppression after the 1 mg dexamethasone test was rare, occurring in four patients (1.1%) overall: 0/64 (0%) in BMI 30.0–39.9 kg/m 2 , 2/202 (1.0%) in BMI 40.0–49.9 kg/m 2 , and 2/86 (2.3%) in BMI ≥50.0 kg/m 2 ; continuous BMI was not associated with post‐dexamethasone cortisol levels. Patients with super obesity demonstrated higher rates of hypertension (36% vs. 18.7–22.2%, p = 0.021) and diabetes (30.2% vs. 16.8–18.7%, p = 0.033). Conclusions: These findings emphasize that elevated post‐dexamethasone cortisol levels in patients with obesity should not be attributed to body weight alone but warrant appropriate evaluation for true hypercortisolism, with clinical interpretation guided by metabolic phenotype rather than BMI.
- 3 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3264-3272
Relationship between body mass index and 1 mg dexamethasone suppression test in patients with obesity
Aims: The 1 mg dexamethasone suppression test (DST) shows variable results in obesity, yet the impact of extreme obesity (body mass index [BMI] ≥50 kg/m 2 ) on hypothalamic–pituitary–adrenal axis function remains poorly characterized. This study evaluated post‐dexamethasone cortisol levels across distinct BMI categories and their associations with metabolic parameters. Materials and Methods: This retrospective study included 352 adults with obesity (BMI ≥30 kg/m 2 ) who underwent 1 mg overnight DST between February 2019 and August 2023. Patients were stratified into three groups: BMI 30.0–39.9 kg/m 2 ( n = 64), BMI 40.0–49.9 kg/m 2 ( n = 202), and BMI ≥50.0 kg/m 2 ( n = 86). Clinical, anthropometric, and laboratory parameters were compared between groups. Results: The cohort had a median age of 41 years and comprised 284 females (80.7%). Post‐dexamethasone cortisol levels showed modest differences across BMI categories (median 0.79, 0.77, and 0.88 μg/dL, respectively; p = 0.038). Inadequate cortisol suppression after the 1 mg dexamethasone test was rare, occurring in four patients (1.1%) overall: 0/64 (0%) in BMI 30.0–39.9 kg/m 2 , 2/202 (1.0%) in BMI 40.0–49.9 kg/m 2 , and 2/86 (2.3%) in BMI ≥50.0 kg/m 2 ; continuous BMI was not associated with post‐dexamethasone cortisol levels. Patients with super obesity demonstrated higher rates of hypertension (36% vs. 18.7–22.2%, p = 0.021) and diabetes (30.2% vs. 16.8–18.7%, p = 0.033). Conclusions: These findings emphasize that elevated post‐dexamethasone cortisol levels in patients with obesity should not be attributed to body weight alone but warrant appropriate evaluation for true hypercortisolism, with clinical interpretation guided by metabolic phenotype rather than BMI.
- 19 May 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (5) , 439-446
Unlocking the diagnostic potential of parathormone washout: a path to accurate parathyroid tumor localization
Accurate tumor localization is necessary for the application of minimally invasive surgery, which is preferred in the treatment of primary hyperparathyroidism. Parathormone-washout (PTH-WO) is parathyroid fine-needle aspiration followed by PTH measurement in the needle washout fluid. This study aimed to determine appropriate cutoff values for the PTH-WO method. A total of 402 PTH-WO assays from 339 patients were included in the study. The diagnostic accuracy of the test was assessed by accepting as a positive result a PTH-WO result higher than the serum PTH level [PTH-WO/serum PTH(PTH ratio)>1]. In addition, a cutoff value for the test was established by evaluating the PTH washout results obtained in comparison with postoperative histopathology. Undiluted test results were not included to obtain a clear numerical value in this evaluation. The results of parathyroid scintigraphy and fine needle aspiration biopsy (FNAB) were compared with postoperative histopathology. While 309 (76.86%) of the PTH-WO procedures were considered positive, 93 (23.13%) were considered negative if the PTH ratio was > 1. When these results were compared with the postoperative histopathology, the test's sensitivity was 92.51%, and the specificity was 100.00%. In the analysis of the remaining 292 PTH-WO samples after excluding the undiluted ones, the sensitivity and specificity of the method were 92.3% and 94.1%, respectively, with a PTH ratio > 0.99. With a cutoff value of 99.5 ng/l for PTH-WO value, 93.1% sensitivity and 94.3% specificity were obtained. The sensitivities of parathyroid scintigraphy and FNAB were 53.4% and 15.3%, respectively. The PTH-WO method is safe and cheap, with high sensitivity and specificity in localizing parathyroid tumor. In cases where radiological methods cannot achieve localization with specified cutoff values, it has high diagnostic accuracy.
- 19 May 2025
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 137 (5) , 439-446
Unlocking the diagnostic potential of parathormone washout: a path to accurate parathyroid tumor localization
Accurate tumor localization is necessary for the application of minimally invasive surgery, which is preferred in the treatment of primary hyperparathyroidism. Parathormone-washout (PTH-WO) is parathyroid fine-needle aspiration followed by PTH measurement in the needle washout fluid. This study aimed to determine appropriate cutoff values for the PTH-WO method. A total of 402 PTH-WO assays from 339 patients were included in the study. The diagnostic accuracy of the test was assessed by accepting as a positive result a PTH-WO result higher than the serum PTH level [PTH-WO/serum PTH(PTH ratio)>1]. In addition, a cutoff value for the test was established by evaluating the PTH washout results obtained in comparison with postoperative histopathology. Undiluted test results were not included to obtain a clear numerical value in this evaluation. The results of parathyroid scintigraphy and fine needle aspiration biopsy (FNAB) were compared with postoperative histopathology. While 309 (76.86%) of the PTH-WO procedures were considered positive, 93 (23.13%) were considered negative if the PTH ratio was > 1. When these results were compared with the postoperative histopathology, the test's sensitivity was 92.51%, and the specificity was 100.00%. In the analysis of the remaining 292 PTH-WO samples after excluding the undiluted ones, the sensitivity and specificity of the method were 92.3% and 94.1%, respectively, with a PTH ratio > 0.99. With a cutoff value of 99.5 ng/l for PTH-WO value, 93.1% sensitivity and 94.3% specificity were obtained. The sensitivities of parathyroid scintigraphy and FNAB were 53.4% and 15.3%, respectively. The PTH-WO method is safe and cheap, with high sensitivity and specificity in localizing parathyroid tumor. In cases where radiological methods cannot achieve localization with specified cutoff values, it has high diagnostic accuracy.
- Open Access
- 23 December 2024
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (2) , 191-201
Clinical Characteristics and Genotype-Phenotype Correlation in the Patients with the Diagnosis of Resistance to Thyroid Hormone Beta
Journal of Clinical Research in Pediatric Endocrinology
- 23 December 2024
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (2) , 191-201
Open AccessClinical Characteristics and Genotype-Phenotype Correlation in the Patients with the Diagnosis of Resistance to Thyroid Hormone Beta
Journal of Clinical Research in Pediatric Endocrinology
- Open Access
- 23 August 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (3) , 1204
Correction: Timing of the repeat thyroid fine-needle aspiration biopsy: does early repeat biopsy change the rate of nondiagnostic or atypia of undetermined significance cytology result?
- 23 August 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (3) , 1204
Open AccessCorrection: Timing of the repeat thyroid fine-needle aspiration biopsy: does early repeat biopsy change the rate of nondiagnostic or atypia of undetermined significance cytology result?
- Open Access
- 10 July 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (3) , 1065-1072
Timing of the repeat thyroid fine-needle aspiration biopsy: does early repeat biopsy change the rate of nondiagnostic or atypia of undetermined significance cytology result?
Purpose: To determine whether early repeat fine needle aspiration biopsy (FNA) has an effect on adequate or atypia of undetermined significance (AUS) cytology rates in thyroid nodules with inadequate or AUS result in the first FNA. Methods: Nodules of patients who underwent repeat biopsy due to insufficient or AUS cytology between 2019–2022 were included. Data of the patients and ultrasonographic, cytological and histopathological results of the nodules were recorded. Additionally, the time between the two biopsies was noted. The first was called “initial” and the second was called “rebiopsy”. Five different paired groups were formed according to the time between two consecutive biopsies; before and after 1 month, 45 days, 2 months, 3 months, and 6 months. The groups were compared in terms of adequate and AUS cytological results. Results: We evaluated 1129 patients with 2187 nodules undergoing FNAB. After excluding nodules with one FNA result and/or missing data, 966 nodules of 628 patients who underwent FNA at least twice were included. Initial cytology was nondiagnostic (ND) in 665 (30.4%) and AUS in 301 (13.8%) nodules. The mean age of the patients was 52.0 ± 11.9 years, and the female sex ratio was 78.8% (n = 495). There were no differences in adequate or AUS rebiopsy results according to the different time interval groups (p > 0.05 for all). AUS result was statistically insignificantly more frequent in nodules with initially AUS nodules when rebiopsy was performed before 1 month in comparison to after 1 month (53.8%, 27.1%; p = 0.054). Accuracy of rebiopsy was also similar in the time intervals groups (p > 0.05 for all). Conclusion: In patients with inadequate or AUS initial biopsy, the rate of adequate or AUS cytology results at rebiopsy did not vary with the timing of repeat biopsy indicating that there may be no need to wait 1 month for a repeat biopsy. In patients with suspicious nodules, biopsy might be repeated before 1 month.
- 10 July 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (3) , 1065-1072
Open AccessTiming of the repeat thyroid fine-needle aspiration biopsy: does early repeat biopsy change the rate of nondiagnostic or atypia of undetermined significance cytology result?
Purpose: To determine whether early repeat fine needle aspiration biopsy (FNA) has an effect on adequate or atypia of undetermined significance (AUS) cytology rates in thyroid nodules with inadequate or AUS result in the first FNA. Methods: Nodules of patients who underwent repeat biopsy due to insufficient or AUS cytology between 2019–2022 were included. Data of the patients and ultrasonographic, cytological and histopathological results of the nodules were recorded. Additionally, the time between the two biopsies was noted. The first was called “initial” and the second was called “rebiopsy”. Five different paired groups were formed according to the time between two consecutive biopsies; before and after 1 month, 45 days, 2 months, 3 months, and 6 months. The groups were compared in terms of adequate and AUS cytological results. Results: We evaluated 1129 patients with 2187 nodules undergoing FNAB. After excluding nodules with one FNA result and/or missing data, 966 nodules of 628 patients who underwent FNA at least twice were included. Initial cytology was nondiagnostic (ND) in 665 (30.4%) and AUS in 301 (13.8%) nodules. The mean age of the patients was 52.0 ± 11.9 years, and the female sex ratio was 78.8% (n = 495). There were no differences in adequate or AUS rebiopsy results according to the different time interval groups (p > 0.05 for all). AUS result was statistically insignificantly more frequent in nodules with initially AUS nodules when rebiopsy was performed before 1 month in comparison to after 1 month (53.8%, 27.1%; p = 0.054). Accuracy of rebiopsy was also similar in the time intervals groups (p > 0.05 for all). Conclusion: In patients with inadequate or AUS initial biopsy, the rate of adequate or AUS cytology results at rebiopsy did not vary with the timing of repeat biopsy indicating that there may be no need to wait 1 month for a repeat biopsy. In patients with suspicious nodules, biopsy might be repeated before 1 month.
- 1 May 2024
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 76 (2)
Fluorescence-guided laparoscopic partial adrenalectomy in adrenal medullary hyperplasia mimicking pheochromocytoma
Article: Fluorescence-guided laparoscopic partial adrenalectomy in adrenal medullary hyperplasia mimicking pheochromocytoma - Minerva Urology and Nephrology 2023 Nov 21 - Minerva Medica - Journals
- 1 May 2024
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 76 (2)
Fluorescence-guided laparoscopic partial adrenalectomy in adrenal medullary hyperplasia mimicking pheochromocytoma
Article: Fluorescence-guided laparoscopic partial adrenalectomy in adrenal medullary hyperplasia mimicking pheochromocytoma - Minerva Urology and Nephrology 2023 Nov 21 - Minerva Medica - Journals